Novo Nordisk announced phase 1b/2a clinical trial results for amycretin this morning. Patients taking the GLP-1 drug lost an average of 9.7% of their weight in 36 weeks. This is the best news Novo ...

TD Cowen analyst Michael Nedelcovych maintained a Buy rating on Novo Nordisk (NVO – Research Report) today. The company’s shares closed yesterday at $81.10. Nedelcovych covers the Healthcare ...

In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of DKK750.00. The company’s shares closed yesterday at ...

Novo Nordisk - which manufactures Wegovy ... without appropriate checks "and the risk to patient safety remains". Image: Pic: Reuters file photo Weight loss jabs, known as GLP-1 receptor agonists ...

Novo Nordisk's stock (NVO) rose more than 8% in Friday trading on news that the company's latest weight-loss product delivered favorable results. The new drug, amycretin, similar to the company's ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, also known as semaglutide, has been approved to reduce the risk of kidney disease worsening, kidney failure, and death from ...

(Image Credits: Pixabay) The United States Food and Drug Administration (USFDA) has approved Novo Nordisk’s Ozempic for reducing the risk of kidney failure and disease progression. According to ...

Novo estimates that CKD affects some 37 million adults in the U.S., with that number likely to rise in the coming years. The condition is also a common complication of Type 2 diabetes, cropping up ...

Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders! Twice in the past two months, the Danish manufacturer of GLP-1 drugs for weight loss and diabetes treatment has reported clinical ...

Novo Nordisk said the Food and Drug Administration approved the diabetes-drug Ozempic to be used to help kidney-disease patients. Ozempic, or semaglutide, can now be used to reduce the risk of ...

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA ...

A next-generation Novo Nordisk obesity drug designed to hit two targets has preliminary clinical data showing 22% weight loss, results that suggest the once-weekly injection could have an edge ...